
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Details : 18-F PSMA-1007 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
November 08, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 177-Lu Vipivotide Tetraxetan
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Advanced Accelerator Applications
Deal Size : $172.0 million
Deal Type : Agreement
Details : Advanced Accelerator Applications (AAA) and Endocyte, Inc., both Novartis companies, successfully completed full-scale development of Pluvicto and also received Breakthrough Therapy designation from the U.S. FDA last year.
Product Name : Pluvicto
Product Type : Radiolabeled Compound
Upfront Cash : $12.0 million
March 29, 2022
Lead Product(s) : 177-Lu Vipivotide Tetraxetan
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Advanced Accelerator Applications
Deal Size : $172.0 million
Deal Type : Agreement

Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
Details : 18-F PSMA-1007 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
February 08, 2021

F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence
Details : 18-F Fluorocholine is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
September 25, 2019
